|
| 37406085 | Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma. | | 2023 |
| 36302899 | Small-molecule inhibition of the archetypal UbiB protein COQ8. | Nat Chem Biol | 2023 |
| 37577663 | Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies. | | 2023 |
| 34958800 | Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition. | Journal of Biological Chemistry | 2022 |
| 35738348 | Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies. | Antiviral Res | 2022 |
| 35403825 | Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype. | ChemMedChem | 2022 |
| 34641454 | Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors. | Molecules | 2021 |
| 33837205 | SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2. | npj Breast Cancer | 2021 |
| 34264955 | Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. | PLoS One | 2021 |
| 33980863 | FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. | NPJ Breast Cancer | 2021 |
| 34461089 | New strategies for targeting kinase networks in cancer. | Journal of Biological Chemistry | 2021 |
| 34606255 | PRM-LIVE with Trapped Ion Mobility Spectrometry and Its Application in Selectivity Profiling of Kinase Inhibitors. | Anal Chem | 2021 |
| 34426604 | High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy. | Sci Rep | 2021 |
| 32847978 | <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK. | Mol Cancer Ther | 2020 |
| 32213714 | Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. | JCI Insight | 2020 |
| 32753473 | Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer. | Molecular Cancer Research | 2020 |
| 32573490 | FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. | J Clin Invest | 2020 |
| 31346082 | Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma. | Proceedings of the National Academy of Sciences of the United States of America | 2019 |
| 30335132 | A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas. | Hum Mol Genet | 2019 |
| 30973735 | Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma. | Journal of Medicinal Chemistry | 2019 |
| 31429028 | Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. | Targeted Oncology | 2019 |
| 31000582 | GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer. | Molecular Cancer Research | 2019 |
| 29072804 | Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclinâ¿¿G Associated Kinase. | ChemMedChem | 2018 |
| 28934561 | Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer. | Annual Review of Pharmacology and Toxicology | 2018 |
| 29982664 | EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. | Neuro Oncol | 2018 |
| 30532236 | Far away from the lamppost. | PLoS Biol | 2018 |
| 29897904 | Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. | PLoS One | 2018 |
| 29309787 | Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2). | Biochemical and Biophysical Research Communications | 2018 |
| 29567993 | Unexplored therapeutic opportunities in the human genome. | Nat Rev Drug Discov | 2018 |
| 29180473 | New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging. | Cancer Res | 2018 |
| 29133594 | Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling. | Mol Cancer Res | 2018 |
| 29472638 | Unexplored therapeutic opportunities in the human genome. | Nat Rev Drug Discov | 2018 |
| 29472518 | Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. | Cancer Res | 2018 |
| 29742358 | Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth. | SLAS Discovery | 2018 |
| 29643987 | Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer. | Oncotarget | 2018 |
| 28273454 | MAP3K4 Controls the Chromatin Modifier HDAC6 during Trophoblast Stem Cell Epithelial-to-Mesenchymal Transition. | Cell Reports | 2017 |
| 28464261 | Measuring Kinase Activity-A Global Challenge. | Journal of Cellular Biochemistry | 2017 |
| 28640223 | Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo. | Metabolites | 2017 |
| 28379424 | Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. | Neuro Oncol | 2017 |
| 28977680 | Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis. | Br J Pharmacol | 2017 |
| 28486691 | Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. | Neuro Oncol | 2017 |
| 28781985 | Pharmacologic targeting of drug-induced enhancers. | Oncoscience (discontinued) | 2017 |
| 29051215 | Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Recepto | Journal of the American Heart Association | 2017 |
| 29209639 | Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer. | Molecular and Cellular Oncology | 2017 |
| 27186656 | Targeting the Breast Cancer Kinome. | Journal of Cellular Physiology | 2017 |
| 28287892 | Landscaping a chromatin response to MEK inhibition. | Cell Cycle | 2017 |
| 28237943 | Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals. | Molecular and Cellular Proteomics | 2017 |
| 28108460 | Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. | Cancer Discov | 2017 |
| 27308566 | Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains. | Molecular and Cellular Oncology | 2016 |
| 27042159 | Weight loss reduces basal-like breast cancer through kinome reprogramming. | Cancer Cell Int | 2016 |